SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as the software sector navigates a significant sell-off driven by "AI fear," sparking intense community debate on whether AI will disrupt or enhance the enterprise giant. Despite news of workforce adjustments and a new government contract, many investors are frustrated by ongoing price declines, viewing it as an oversold opportunity potentially exacerbated by market manipulation.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is buzzing with conversation after its recent financial update, which showcased impressive membership growth and an optimistic 2026 outlook, fueling bullish enthusiasm despite concerns over a quarterly performance miss and ongoing uncertainty surrounding broader healthcare policy.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending due to mixed community reactions following its Q4 earnings report, which showed a beat on adjusted EPS but fueled ongoing concerns about revenue growth and increasing debt. The community is sharply divided between those who see a value opportunity amidst its current valuation and others drawing negative parallels to the broader fintech sector and companies like PayPal.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is at a pivotal moment as its Q4 earnings report is highly anticipated, with the community actively debating whether the recent significant sell-off presents a buying opportunity. Despite broader software sector concerns and increased competition, many highlight Datadog's critical role in monitoring AI-driven cloud infrastructure and its strong customer relationships, while some analysts have adjusted price targets reflecting mixed expectations for performance amidst a valuation reset.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following strong Q4 earnings, optimistic FY2026 guidance, and reaffirmed targets for profitability by 2027, with the community actively discussing its potential as the 'Amazon of Africa' amidst bullish analyst coverage.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to its strong Q4 earnings beat and robust subscriber growth, alongside recent premium subscription price increases. The community is widely debating if these positive catalysts, coupled with new AI features and video content, can reverse the stock's recent downtrend and its perceived correlation with Netflix's performance, as many consider it oversold.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is trending following its earnings report, which revealed a revenue miss primarily due to weak North American demand, sparking community discussions about its recent rally and overbought conditions despite an earnings per share beat and strong performance in the broader consumer staples sector.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending as investors digest mixed Phase 2b results for its alopecia areata drug, with community discussion focused on the significance of efficacy data achieved after excluding some patients and the drug's strong safety profile, alongside ongoing speculation about a potential Lilly settlement.

S&P Global, Inc. engages in the provision of transparent and independent ratings, benchmarks, analytics, and data to the capital and commodity markets worldwide. It operates through the following segments: Market Intelligence, Ratings, Commodity Insights, Mobility, Indices, and Engineering Solutions. The Market Intelligence segment provides multi-asset-class data and analytics integrated with purpose-built workflow solutions. The Ratings segment is involved in credit ratings, research, and analytics, offering investors and other market participants information, ratings, and benchmarks. The Commodity Insights segment focuses on information and benchmark prices for the commodity and energy markets. The Mobility segment offers solutions serving the full automotive value chain including vehicle manufacturers, automotive suppliers, mobility service providers, retailers, consumers, and finance and insurance companies. The Engineering Solutions segment engages in advanced knowledge discovery technologies, research tools, and software-based engineering decision engines to advance innovation, maximize productivity, improve quality, and reduce risk. The company was founded by James H. McGraw and John A. Hill in 1917 and is headquartered in New York, NY.

S&P Global Inc

S&P Global is trending as its latest guidance signaled slower growth and missed analyst estimates, fueling community discussion amidst broader concerns that powerful new AI models, such as Anthropic's Claude Opus 4.6, could significantly disrupt the financial data and analytics sector, though many also view the sharp sell-off as an overreaction and a buying opportunity.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is trending due to the abrupt departures of its CFO and General Counsel amid an ongoing accounting review, delayed SEC filings, and internal control weaknesses, which has the community intensely debating severe credibility risks and drawing comparisons to other companies that faced similar financial reporting challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.5% - Should You Sell?

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.5% - Here's What Happened...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 7.4% Higher - Still a Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.4% - Here's Why...

<ul class="summary-bullets"><li>On Stocktwits, retail sentiment around IOVA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. In the three months through the end of September,</li><li>Iovance reported total product revenue of $68 million, including about $58 million from Amtagvi sales in the U.S.</li><li>In November, the company said that it expects full year 2025 revenue of $250 million to $300 million. &nbsp;</li></ul>Shares of Iovance Biotherapeutics Inc. (IOVA) garnered retail interest on Monday, as shares climbed up 8% amid anticipation from investors for positive announcements, and takeover hopes. &nbsp;On Stocktwits, retail sentiment around IOVA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.Iovance is a commercial stage immuno-oncology company. It is seeking to deliver tumor-infiltrating lymphocyte (TIL) therapies for patients with cancer. TIL therapy is a personalized, one-time immunotherapy that extracts a patient's own, naturally occurring T-cells from their tumor, expands them to billions in a lab, and infuses them back to fight advanced cancers.<h2 class="st-heading-2">What Do Stocktwits Users Have To Say?</h2>A Stocktwits user highlighted that the company hasn’t made announcements in the recent weeks. “They've had their head down working at the grindstone. Its time for several updates!” they wrote.<stembedurl>https://www.stocktwits.com/BioCrazy1/message/642913966</stembedurl>Another highlighted takeover opportunities.<stembedurl>https://www.stocktwits.com/beachsidefreddy/message/642912870</stembedurl>Another user opined that IOVA management must have a chat with Merck in light of reports that the pharma giant is no longer in talks to acquire the cancer drug developer Revolution Medicines.<stembedurl>https://www.stocktwits.com/TopCharts/message/642896481</stembedurl><h2 class="st-heading-2">Iovance Pipeline</h2>In the three months through the end of September, Iovance reported total product revenue of $68 million, including about $58 million from Amtagvi sales in the U.S. Amtagvi is FDA-approved for the treatment of metastatic melanoma.In November, the company said that it expects full year 2025 revenue of $250 million to $300 million. 2025 marks the first full calendar year of Amtagvi sales. Analysts on average expect the company to report total revenue of $259.45 million.<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> has fallen 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/whats-driving-the-uptick-in-evtv-stock-today/cmy7yYCR4hh">What’s Driving The 38% Uptick In EVTV Stock Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Iovance Biotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IOVA Shares Jump 8% — What’s Retail Expecting?

Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.

Equity

Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.


Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.4% - What's Next?

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.4% - Here's What Happened...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1% - Here's What Happened

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1% - Should You Sell...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7% - Still a Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 8.7% - Here's Why...

Iovance Biotherapeutics, Inc. $IOVA Position Increased by Squarepoint Ops LLC

Squarepoint Ops LLC grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 115.2% in the 2nd quarter, according to the company in its most recent Form 13F filing...

Mirador Capital Partners LP Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA

Mirador Capital Partners LP purchased a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the...

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7% - Should You Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7% - What's Next...

Voss Capital LP Acquires New Shares in Iovance Biotherapeutics, Inc. $IOVA

Voss Capital LP acquired a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities...

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$2.60
Prev Close	$2.53
Open	$2.52
Dividend Yield	0.00%
50-Day Moving Average	$2.50
Beta	1.61
Avg. Volume	12.83M
PE Ratio	-2.11

52-Week High	$6.09
52-Week Low	$1.64
Market Capitalization	$1B
EPS (Annual)	-$1.28
Price to Book	1.39
Revenue Per Employee	$195,787.59
Enterprise Value/EBITDA	N/A

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IOVA News

IOVAIovance Biotherapeutics Inc